$258.64
2.050.8%
Last update: Nov 11, 3:54 PM
Ascendis Pharma AS
ASNDNASDAQ
Ascendis Pharma AS rose 27.6% from $201.16 to $256.59, ahead of the S&P 500's +9.8%. Its worst day was Sep 15 (−9.5%), and its low came Dec 9 at $196.63.
Nov 11, 2025 – Nov 10, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.17 missed the $-0.41 estimate on $249.8M revenue (est. $248.6M).
+3.6% · S&P 500 −1.7%
Ascendis Pharma AS closed at its lowest level of the year, 2.3% below where the year started.
Story events cover the past 12 months · Times ET
−5.1% · S&P 500 −0.1%
Ascendis Pharma AS shares fell 6.8%, while the S&P 500 fell 0.0%.
−6.8% · S&P 500 0.0%
EPS of $-0.64 missed the $-0.06 estimate on $288.1M revenue (est. $289.7M).
−1.5% · S&P 500 −1.5%
EPS of $0.32 beat the $0.21 estimate on $288.8M revenue (est. $318.1M).
+4.3% · S&P 500 −0.3%
Ascendis Pharma AS shares rose 9.9%, while the S&P 500 rose 0.1%.
+9.9%, the year's best day · S&P 500 +0.1%
Ascendis Pharma AS closed at its highest level of the year, 37.8% above where the year started.
+3.8% · S&P 500 −0.3%
EPS of $1.05 beat the $0.78 estimate on $394.4M revenue (est. $353.8M).
−3.6% · S&P 500 +0.7%
- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and
−9.5%, the year's worst day · S&P 500 −0.5%
Where it ended: a close of $256.59 on Nov 10, 2026. Up next: Q3 2026 earnings on Nov 12, 2026 (EPS est. $1.13, revenue est. $417.2M).
Nothing in the past 12 months.
All ASND dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ASND and SPY from Benzinga historical bars. Not investment advice.
